leflunomide has been researched along with Besnier-Boeck Disease in 10 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 9.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 7.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 5.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "Leflunomide has been reported as an alternative therapy in sarcoidosis." | 3.77 | Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. ( Bandyopadhyay, D; Chapman, JT; Culver, DA; Lazar, CA; Parambil, JG; Pearson, K; Sahoo, DH; Xu, M, 2011) |
| " A diagnosis of stage 2 sarcoidosis with pleural involvement was made and treatment with prednisone was started." | 3.75 | A 50-year-old man with stage 2 sarcoidosis with pleural involvement. ( Arrossi, A; Modrykamien, A; Reddy, A, 2009) |
| "Effective treatment of sarcoidosis potentially requires simultaneous modulation both M1/M2 polarization instead of suppressing one pathway over the other to restore immune competent and inactive (M0) macrophages." | 2.58 | Potential immunotherapies for sarcoidosis. ( Crouser, ED; Le, V, 2018) |
| "Sarcoidosis is a systemic, granulomatous disease that can affect multiple organs and has a variable clinical course." | 2.49 | Current therapy in sarcoidosis, the role of existing drugs and future medicine. ( Deneer, VH; Grutters, JC; van Moorsel, CH; Vorselaars, AD, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le, V | 1 |
| Crouser, ED | 1 |
| Vorselaars, AD | 1 |
| van Moorsel, CH | 1 |
| Deneer, VH | 1 |
| Grutters, JC | 1 |
| Bohelay, G | 1 |
| Bouaziz, JD | 1 |
| Nunes, H | 1 |
| Rybojad, M | 1 |
| Bagot, M | 1 |
| Petit, A | 1 |
| Laroche, L | 1 |
| Au, S | 1 |
| Mirsaeidi, M | 1 |
| Aronson, IK | 1 |
| Sweiss, NJ | 1 |
| Baughman, RP | 2 |
| Lower, EE | 2 |
| Modrykamien, A | 1 |
| Arrossi, A | 1 |
| Reddy, A | 1 |
| Sahoo, DH | 1 |
| Bandyopadhyay, D | 1 |
| Xu, M | 1 |
| Pearson, K | 1 |
| Parambil, JG | 1 |
| Lazar, CA | 1 |
| Chapman, JT | 1 |
| Culver, DA | 1 |
| Majithia, V | 1 |
| Sanders, S | 1 |
| Harisdangkul, V | 1 |
| Wilson, JG | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
4 reviews available for leflunomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
Potential immunotherapies for sarcoidosis.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Granuloma; Humans; Immunotherapy; Leflunom | 2018 |
Current therapy in sarcoidosis, the role of existing drugs and future medicine.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopri | 2013 |
Treatment of Sarcoidosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Clinical Trials as Topic; Drug Administration Schedule; Gran | 2015 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
1 trial available for leflunomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
Leflunomide for chronic sarcoidosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug Therapy, Combination; Fe | 2004 |
5 other studies available for leflunomide and Besnier-Boeck Disease
| Article | Year |
|---|---|
Striking leflunomide efficacy against refractory cutaneous sarcoidosis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; | 2014 |
Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.
Topics: Adalimumab; Biopsy; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Middle Aged; | 2014 |
A 50-year-old man with stage 2 sarcoidosis with pleural involvement.
Topics: Antirheumatic Agents; Dyspnea; Humans; Isoxazoles; Leflunomide; Lung; Male; Middle Aged; Pleural Dis | 2009 |
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis.
Topics: Adjuvants, Immunologic; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Sarcoidosis; Sar | 2011 |
Successful treatment of sarcoidosis with leflunomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Immunosuppressive Agents; Isoxazoles; Leflun | 2003 |